general transcription factor IIH subunit 2B (pseudogene)Genealiases: []
Q-omics provides the consensus-scored GTF2H2B profile across patient tissues and cancer cell-line models. GTF2H2B expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, GTF2H2B is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, GTF2H2B RNA expression shows 16,687 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KICH, KIRC, and UVM as cancer lineages where GTF2H2B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GTF2H2B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GTF2H2B survival associations across molecular data types. GTF2H2B RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GTF2H2B RNA expression–survival associations across cancer types. High GTF2H2B expression shows unfavorable associations in KICH, THCA and LIHC, but favorable associations in HNSC, DLBC and SKCM. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KICH as the clearest survival context for GTF2H2B RNA expression.
This table summarizes GTF2H2B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for GTF2H2B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GTF2H2B shows lower tumor expression in KIRC, KICH and THCA and higher tumor expression in LIHC, BRCA and CHOL. The KIRC box plot shows higher GTF2H2B RNA expression in normal versus tumor tissue (log2 FC = −0.264, t-test p < 0.001).
This table shows molecular features associated with GTF2H2B in patient tissues and cancer cell lines. In patient samples, GTF2H2B shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, GTF2H2B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and NCI60_ALL.
